METASTATIC SOFT TISSUE SARCOMA

This study tests a combination of two drugs, HDM201 and pazopanib, in people with advanced soft tissue sarcoma that has spread. The goal is to find the safest dose and see if the combo can help control the cancer. About 47 adults with a specific genetic type (P53 wild-type) will …

This study tests whether combining the targeted drug cabozantinib with two immunotherapy drugs (nivolumab and ipilimumab) can shrink tumors in people with metastatic soft tissue sarcoma that has not responded to prior treatments. About 105 participants will receive the combinatio…

This early-stage trial tests several new drug combinations in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if these combinations can shrink tumors or slow their growth. About 352 participants with cancers…

This study tests whether adding the targeted drug cabozantinib to immunotherapy (ipilimumab and nivolumab) works better than immunotherapy alone for people with advanced soft tissue sarcoma that has spread. About 66 adults with specific sarcoma types will receive either the combo…

This study tests whether adding two immunotherapy drugs (zalifrelimab and balstilimab) to standard chemotherapy (doxorubicin) can help people with advanced or metastatic soft tissue sarcoma live longer without their cancer growing. About 65 adults aged 18-100 who have not had pri…

This study tests whether combining cabozantinib (a targeted drug) with temozolomide (chemotherapy) can slow or stop tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants receive bo…

This study tests a new combination of two drugs, lurbinectedin and doxorubicin, for people with advanced leiomyosarcoma, a rare soft tissue cancer. The first part finds a safe dose, and the second part compares the combination to lurbinectedin alone to see which works better. Abo…